keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/28418307/serogroup-b-meningococcal-disease-vaccine-recommendations-at-a-university-new-jersey-usa-2016
#1
Heidi M Soeters, Jill Dinitz-Sklar, Prathit A Kulkarni, Jessica R MacNeil, Lucy A McNamara, Elizabeth Zaremski, How-Yi Chang, Eduardo Lujan, Dan Granoff, Melodee Lasky, Barbara Montana
In response to a university-based serogroup B meningococcal disease outbreak, the serogroup B meningococcal vaccine Trumenba was recommended for students, a rare instance in which a specific vaccine brand was recommended. This outbreak highlights the challenges of using molecular and immunologic data to inform real-time response.
May 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28410825/active-offer-of-vaccinations-during-hospitalization-improves-coverage-among-splenectomized-patients-an-italian-experience
#2
Maria Serena Gallone, Carmen Martino, Michele Quarto, Silvio Tafuri
In 2014, an Italian hospital implemented a protocol for pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines offer to splenectomized patients during their hospitalization. After 1 year, coverage for recommended vaccinations increased from 5.7%-66.7% and the average time between splenectomy and vaccines administration decreased from 84.7-7.5 days.
April 11, 2017: American Journal of Infection Control
https://www.readbyqxmd.com/read/28379053/influence-of-the-co-administration-of-heptavalent-conjugate-vaccine-pcv7-tt-on-the-immunological-response-elicited-by-va-mengoc-bc%C3%A2-and-heberpenta%C3%A2-l-in-rabbits
#3
Carlos Espinosa-Viñals, Dagmar García-Rivera, Laura Rodríguez Noda, Aylín Amador Gómez, Milagros Nicot, Orialys Valle, Juan F Núñez, Yanet Martin, Darielys Santana, Yury Valdés, Vicente Vérez Bencomo
Finlay Vaccine Institute is developing a new heptavalent conjugate vaccine against Streptococcus pneumoniae. As infants are the target population, PCV7-TT will be necessarily co-administered with other vaccines, and then, the interactions represent a concern. The aim of this work is to evaluate the possible immunological interferences in rabbits as animal experimental model. Rabbits were immunized with Heberpenta®-L, VA-MENGOC-BC®, and PCV7-TT. Blood samples were taken fourteen days after final immunization for obtaining sera...
April 5, 2017: Immunological Investigations
https://www.readbyqxmd.com/read/28375507/tetanus-diphtheria-pertussis-vaccine-may-suppress-the-immune-response-to-subsequent-immunization-with-pneumococcal-crm197-conjugate-vaccine-coadministered-with-quadrivalent-meningococcal-tt-conjugate-vaccine-a-randomized-controlled-trial%C3%A2
#4
Mohamed Tashani, Leon Heron, Melanie Wong, Harunor Rashid, Robert Booy
Background: : Due to their antigenic similarities, there is a potential for immunological interaction between tetanus/diphtheria-containing vaccines and carrier proteins presented on conjugate vaccines. The interaction could, unpredictably, result in either enhancement or suppression of the immune response to conjugate vaccines if they are injected soon after or concurrently with diphtheria or tetanus toxoid. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage of 2015...
July 1, 2017: Journal of Travel Medicine
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#5
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
April 10, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28369464/four-component-meningococcal-capsular-group-b-vaccine-in-preterm-infants
#6
Manish Sadarangani, Sheula Barlow, Mark Anthony, Andrew J Pollard
No abstract text is available yet for this article.
March 20, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28368526/licensed-meningococcal-serogroup-b-vaccine-induced-immunity-against-invasive-disease-does-not-reflect-protection-against-nasal-colonization-in-a-humanized-mouse-model
#7
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background: The 4CMenB vaccine is an outer membrane vesicle and recombinant protein-based vaccine recently licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods: Employing a 'humanized' transgenic mouse model of nasal colonization, a systematic approach was taken to estimate the potential for carriage prevention against antigenically-diverse Neisseria meningitidis strains, and to compare this protection to an invasive meningococcal disease challenge model...
March 27, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28366725/meningococcal-serogroup-b-strain-coverage-of-the-multicomponent-4cmenb-vaccine-with-corresponding-regional-distribution-and-clinical-characteristics-in-england-wales-and-northern-ireland-2007-08-and-2014-15-a-qualitative-and-quantitative-assessment
#8
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
March 30, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28362241/safety-of-a-meningococcal-group-b-vaccine-used-in-response-to-two-university-outbreaks
#9
Jonathan Duffy, Peter Johnsen, Mary Ferris, Mary Miller, Kevin Leighton, Mark McGilvray, Lucy McNamara, Lucy Breakwell, Yon Yu, Tina Bhavsar, Elizabeth Briere, Manisha Patel
OBJECTIVE: To assess the safety of MenB-4C vaccine. PARTICIPANTS: Undergraduates, dormitory residents, and persons with high-risk medical conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 12/2013 through 11/2014. METHODS: Adverse events (AEs) were identified by 15 minutes of observation post-vaccination, spontaneous reports, surveys, and hospital surveillance. Causality was assessed for serious adverse events (SAEs)...
March 31, 2017: Journal of American College Health: J of ACH
https://www.readbyqxmd.com/read/28356256/recent-progress-in-the-prevention-of-serogroup-b-meningococcal-disease
#10
Ian M Feavers, Martin C J Maiden
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of four decades vaccine development has focused on sub-capsular, protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations...
March 29, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28352634/surveillance-of-australian-hajj-pilgrims-for-carriage-of-potentially-pathogenic-bacteria-data-from-two-pilot-studies
#11
Mohammad Irfan Azeem, Mohamed Tashani, Al-Mamoon Badahdah, Leon Heron, Kristen Pedersen, Neisha Jeoffreys, Jen Kok, Elizabeth Haworth, Dominic E Dwyer, Grant Hill-Cawthorne, Harunor Rashid, Robert Booy
AIM: To estimate the pharyngeal carriage rate of Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus aureus (S. aureus) among Australian Hajj pilgrims. METHODS: In 2014, surveillance was conducted in two phases among Australian Hajj pilgrims: The first phase during Hajj in Mina, and the second phase soon after returning home to Australia. Nasopharyngeal or oropharyngeal swabs were taken from participants then tested, firstly by nucleic acid testing, and also by standard culture...
March 16, 2017: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/28351732/prevalence-of-factor-h-binding-protein-sub-variants-among-neisseria-meningitidis-in-china
#12
Fenglin Shi, Aiyu Zhang, Bingqing Zhu, Yuan Gao, Li Xu, Yixing Li, Zundong Yin, Junhong Li, Na Xie, Zhujun Shao
OBJECTIVE: To study the prevalence of the fHbp genes in Neisseria meningitidis (N. meningitidis) isolates for further evaluation and development of serogroup B meningococcal vaccines in China. METHODS: A panel of 1012 N. meningitidis strains was selected from the national culture collection from 1956 to 2016, according to the years of isolation, locations, and strain sources. These were tested by FHbp variant typing. Multi-locus sequence typing (MLST) was performed on 822 of these samples, including 242 strains from clinical strains and 580 carrier-derived strains...
March 25, 2017: Vaccine
https://www.readbyqxmd.com/read/28347501/knowledge-attitudes-beliefs-and-behaviors-of-university-students-faculty-and-staff-during-a-meningococcal-serogroup-b-outbreak-vaccination-program
#13
D M MacDougall, J M Langley, L Li, L Ye, D MacKinnon-Cameron, K A Top, S A McNeil, B A Halperin, A Swain, J A Bettinger, E Dubé, G De Serres, S A Halperin
OBJECTIVES: During an outbreak of invasive meningococcal B disease on a university campus, we explored the knowledge, attitudes, beliefs, and behaviors of members of the university community in relation to the disease, the vaccine, and the vaccination program. DESIGN: All students, faculty and staff were invited by email to participate in a 71-item online survey, which was administered after completion of the mass clinics for the first and second doses of a meningococcal B vaccination program...
March 24, 2017: Vaccine
https://www.readbyqxmd.com/read/28344804/multicomponent-meningococcal-b-vaccination-4cmenb-of-adolescents-and-college-students-in-the-united-states
#14
REVIEW
Angelika Banzhoff
Meningococcal disease is rare, easily misdiagnosed, and potentially deadly. Diagnosis in the early stages is difficult and the disease often progresses extremely rapidly. In North America, the incidence of invasive meningococcal disease (IMD) is highest in infants and young children, with a secondary peak in adolescents, a population predominantly responsible for the carriage of disease. Neisseria meningitidis serogroup B (MenB) accounts for a large proportion of meningococcal disease in North America, with documented outbreaks in three universities in the United States (US) during 2008-2013...
February 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28343777/neisseria-meningitidis-nasopharyngeal-carriage-during-the-hajj-a-cohort-study-evaluating-the-need-for-ciprofloxacin-prophylaxis
#15
Ziad A Memish, Jaffar A Al-Tawfiq, Malak Almasri, Esam I Azhar, Muhammad Yasir, Muneera S Al-Saeed, Huda Ben Helaby, Ray Borrow, Abdulhafeez Turkistani, Abdallah Assiri
BACKGROUND: The annual Muslim pilgrimage has the potential of increase risk for acquisition of Neisseria meningitidis. Here, we evaluate the Hajj impact on the prevalence of N. meningitidis carriage in a paired and non-paired cohort of pilgrims. Secondary objectives were to calculate the compliance with recommended vaccination. METHODS: This is a prospective paired (arriving and departing), non-paired arriving and non-paired departing cohort study with the collection of nasopharyngeal samples at the start and the end of the Hajj...
March 23, 2017: Vaccine
https://www.readbyqxmd.com/read/28334397/does-post-implementation-vaccine-effectiveness-data-support-pre-implementation-predictions-of-4cmenb-utility
#16
Jamie Findlow, Ray Borrow
Meningococcal serogroup B vaccines have been licensed on the basis of safety and immunogenicity data without efficacy studies. Establishing the breadth of coverage of these new vaccines has proved difficult and relied on correlates of protection such as serum bactericidal antibody and a novel assays such as the meningococcal antigen typing system. The demonstration of the effectiveness of 4CMenB in a reduced infant dose schedule together with detailed phenotypic and genotypic information gained from isolates and sera from cases of invasive MenB disease in vaccine eligible infants will enable a re-evaluation of our knowledge of correlates of protection...
March 1, 2017: Pathogens and Disease
https://www.readbyqxmd.com/read/28318767/immunogenicity-and-safety-of-concomitant-administration-of-meningococcal-serogroup-b-4cmenb-and-serogroup-c-menc-crm-vaccines-in-infants-a-phase-3b-randomized-controlled-trial
#17
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). METHODS: Infants (N=251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5months (M3, M5) and a booster at 12months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12...
March 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28314560/the-epidemiology-of-invasive-meningococcal-disease-in-eu-eea-countries-2004-2014
#18
Robert Whittaker, Joana Gomes Dias, Miriam Ramliden, Csaba Ködmön, Assimoula Economopoulou, Netta Beer, Lucia Pastore Celentano
BACKGROUND: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction. METHODS: We analysed IMD surveillance data by age, gender, serogroup, country and outcome...
March 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28290948/mortality-surveillance-for-infectious-diseases-in-the-u-s-department-of-defense-1998-2013
#19
Robert N Potter, Ladd A Tremaine, Joel C Gaydos
INTRODUCTION: The Mortality Surveillance Division (MSD) of the U.S. Armed Forces Medical Examiner System was established in 1998 to improve surveillance for all military deaths although emphasizing deaths from infectious diseases. Establishment of the MSD was part of the 1997 Department of Defense initiative to improve surveillance and response for emerging infectious diseases. Before 1998, mortality surveillance was limited to compiling information from death certificates, a system that provided limited useful information and lacked the timeliness needed to take meaningful action to address emerging infectious disease threats...
March 2017: Military Medicine
https://www.readbyqxmd.com/read/28279715/characteristics-and-changes-in-invasive-meningococcal-disease-epidemiology-in-france-2006-2015
#20
I Parent du Chatelet, A E Deghmane, D Antona, E Hong, L Fonteneau, M K Taha, D Lévy-Bruhl
OBJECTIVES: This work aimed to describe the epidemiology of invasive meningococcal disease (IMD) in France, 2006-2015, including group- and genotype-specific disease burden, incidence trends before and after introduction of meningococcal C conjugate vaccines (MCCV) in 2010, and factors influencing the case fatality rate. METHODS: Mandatory notification data on incidence and IMD case characteristics were used. Genotyping of invasive strains and whole genome sequencing were performed by the French National Reference Center...
March 7, 2017: Journal of Infection
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"